EAACI Congress 2024: นวัตกรรมและความก้าวหน้าในการรักษาโรคภูมิแพ้
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
ในระหว่างการประชุมจะมีการนำเสนอเซสชันทางวิทยาศาสตร์มากกว่า 150 ครั้ง โดยมุ่งเน้นที่ความก้าวหน้าทางวิทยาศาสตร์สิ่งแวดล้อม โรคภูมิแพ้อาหาร นวัตกรรมในการใช้ภูมิคุ้มกันบำบัดและโรคภูมิแพ้ในเด็ก และอื่นๆ...
Congreso EAACI 2024: Innovación y Avances en el Tratamiento de Alergias
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Durante el congreso se presentarán más de 150 sesiones científicas centradas en los avances en ciencia medioambiental, alergias alimentarias, innovaciones en inmunoterapia o alergias pediátricas,...
Congresso da EAACI 2024: Inovação e Avanços no Tratamento da Alergia
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Durante o congresso serão apresentadas mais de 150 sessões científicas, centradas nos avanços da ciência ambiental, alergias alimentares, inovações em imunoterapia e alergias pediátricas, entre...
קונגרס EAACI 2024: חדשנות והתקדמות בטיפול באלרגיה
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
במהלך הקונגרס יוצגו למעלה מ-150 מושבים מדעיים, שיתמקדו בין היתר בהתקדמות במדעי הסביבה, אלרגיות למזון, חידושים באימונותרפיה ואלרגיות ילדים.רפואה מדויקת, בינה מלאכותית, אימונותרפיה ומודולטורים...
EAACI Congress 2024：創新與過敏治療進展
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
大會期間將呈獻超過 150 場科學會議，重點關注環境科學、食物過敏、免疫療法創新和兒童過敏等方面的進展。精準醫療、AI、免疫療法和免疫調節劑將匯聚在此次最大型的過敏和免疫學大會上。大會將於 5 月 31 日至 6 月 3 日在西班牙華倫西亞舉行。 華倫西亞，西班牙, April 30, 2024 (GLOBE NEWSWIRE) -- 歐洲過敏和臨床免疫學會 (European...
Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
April 25, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
April 17, 2024 06:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
April 08, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...